Sign Up to like & get
recommendations!
1
Published in 2019 at "Blood Cancer Journal"
DOI: 10.1038/s41408-019-0248-y
Abstract: Few reports suggested a prognostic impact of Wilms‘ Tumor-1 (WT1)-mRNA overexpression in MDS, but translation into clinical routine was hampered by limited patients numbers, differing sample sources, non-standardized methods/cut-offs. To evaluate whether WT1-mRNA expression yields…
read more here.
Keywords:
wt1 mrna;
prognostic impact;
mrna expression;
wt1 ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138377
Abstract: Introduction. Hypomethylating agents azacitidine (AZA) and decitabine are standard of care for myelodysplastic syndromes (MDS). Considering the result of the secondary analysis of the AZA-001 trial showing 91% of first responses occurred within 6 cycles,…
read more here.
Keywords:
wt1 mrna;
response;
three cycles;
cycles aza ... See more keywords